Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

October 26, 2020

Study Completion Date

April 29, 2021

Conditions
Parkinson's Disease
Interventions
DRUG

Placebo

Administered as specified in the treatment arm

DRUG

BIIB054

Administered as specified in the treatment arm.

Trial Locations (75)

6020

Research Site, Innsbruck

10017

NYU Langone Health Center, New York

10032

Research Site, New York

15213

University of Pittsburgh Medical Center Health System, Pittsburgh

19107

Research Site, Philadelphia

20122

Research Site, Milan

20132

Ospedale San Raffaele, Milan

Research Site, Milan

27157

Wake Forest Baptist Health, Winston-Salem

27705

Research Site, Durham

28006

Research Site, Madrid

28007

Research Site, Madrid

28034

Research Site, Madrid

28938

Research Site, Móstoles

29425

Medical University of South Carolina, Charleston

31008

Clinica Universidad de Navarra, Pamplona

31059

Research Name, Toulouse

32224

Mayo Clinic Hospital, Jacksonville

32806

Bioclinica Research, Orlando

33486

Parkinson's Disease and Movement Disorders Centerf, Boca Raton

33616

USF Health Byrd Institute, Tampa

34128

Paracelsus-Elena-Klinik, Kassel

35233

University of Alabama at Birmingham, Birmingham

37232

Research Site, Nashville

40139

Ospedale Bellaria, Bologna

41013

Research Site, Seville

44093

CHU Nantes - Hopital Nord Laënnec, Nantes

44106

The Cleveland Clinic Foundation, Cleveland

44791

Research Site, Bochum

48334

Quest Research Institute, Farmington Hills

48903

Biocruces Health Research Institute, Barakaldo

52074

Universitaetsklinikum Aachen AOeR, Aachen

53226

Medical College of Wisconsin, Milwaukee

56126

Research Site, Pisa

59037

Hopital Roger Salengro - CHU Lille, Lille

60611

Northwestern University PD and Movement Disorders Center, Chicago

60612

Research Site, Chicago

66160

University of Kansas Medical Center Research Institute, Kansas City

70121

Ochsner Health System, New Orleans

75013

Research Site, Paris

77030

Research Site, Houston

80045

University of Colorado Health, Aurora

80113

Rocky Mountain Movement Disorders Center, PC, Englewood

80138

Seconda Università degli Studi di Napoli, Napoli

81675

Klinikum rechts der Isar der TU Muenchen, Munich

84131

Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno

85013

St. Joseph's Hopsital & Medical Center- Barrow Neurological Institute, Phoenix

86077

I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo, Pozzilli

89081

Universitaetsklinikum Ulm, Ulm

90048

Cedars Sinai, Los Angeles

94010

Hôpital Henri Mondor, Créteil

94158

University of California San Francisco Medical Center, San Francisco

94305

Research Site, Stanford

95125

Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico, Catania

97080

Universitaetsklinikum Wuerzburg, Würzburg

98034

Booth Gardner Parkinson's Care Center at Evergreen Health, Kirkland

99204

Inland Northwest Research, Spokane

3109601

Research Site, Haifa

6423906

Research Site, Tel Aviv

92093-0886

Research Site, La Jolla

02114

Massachusetts General Hospital, Boston

02118

Boston University Medical Center, Boston

M5T 2S8

University Health Network, Toronto

H3A 2B4

Montreal Neurological Institute Clinical Research Unit, Montreal

00163

IRCCS San Raffaele, Roma

05100

Azienda Ospedaliera Santa Maria di Terni, Terni

08190

Hospital General de Catalunya, Sant Cugat Del Vallés

08036

Hospital Clinic De Barcalona, Barcelona

08041

Hospital Santa Creu i Sant Pau, Barcelona

CB2 0QQ

Research Site, Cambridge

M6 8HD

Salford Royal, Salford

OX3 9DU

Research Site, Oxford

NE4 5PL

Clinical Ageing Research Unit, Newcastle upon Tyne

S10 2JF

Royal Hallamshire Hospital, Sheffield

WC1N 3BG

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03318523 - Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biotech Hunter | Biotech Hunter